Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: An article of footwear includes an upper, an outsole, and a midsole disposed between the upper and the outsole. The outsole is attached to the upper and has a ground-engaging surface. The midsole has a series of walls that define a series of channels extending substantially perpendicular to a longitudinal axis of the midsole and along an entire length of the midsole. The series of channels are isolated from one another and each channel receives a quantity of particulate matter therein.

Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: A computer implemented technique of tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location is presented.

Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).

Abstract: A computer implemented technique of tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location is presented.

Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.